IL-17E Human, HEK
HEK293.
interleukin-25 isoform 1, interleukin 25, IL17E, IL-17E, IL25, IL-25, interleukin-17E, interleukin-25.
Greater than 95.0% as determined by SDS-PAGE.
Description
IL-17E Human Recombinant produced in HEK293 cells is a single, non-glycosylated polypeptide chain containing 154 amino acids (33-177a.a) and having a molecular mass of 17.8kDa.
IL-17E is fused to a 6 amino acid His-tag at C-terminus & purified by proprietary chromatographic techniques.
Product Specs
IL-17E, also known as IL-25, shares sequence similarity with IL-17. It activates NF-kappaB and stimulates the production of IL-8. Both IL-17E and IL-17B bind to the IL-17BR cytokine receptor. As a pro-inflammatory cytokine, IL-25 promotes Th2-type immune responses. Intracellular JNK, p38 MAPK, and NF-kappaB activity differentially regulate the upregulation of costimulation-induced IL-17E receptors and the release of cytokines and chemokines from IL-17E-treated, costimulated T helper cells. Blocking interleukin-25 prevents airway hyperresponsiveness, a key characteristic of clinical asthma. Innate effector eosinophils and basophils produce IL-25, which amplifies allergic inflammation by enhancing the survival and function of TSLP-DC-activated adaptive Th2 memory cells. In a transgenic mouse model, IL-25 overexpression leads to increased Th2 cytokine expression, growth retardation, jaundice, and multi-organ inflammation. IL-25 contributes to eosinophilic inflammation by acting on lung fibroblasts, highlighting its role in asthma pathophysiology. While IL-17E amplifies TH2 cell-mediated allergic airway inflammation, it does not directly induce it in vivo.
Recombinant human IL-17E, produced in HEK293 cells, is a single, non-glycosylated polypeptide chain comprising 154 amino acids (33-177). It has a molecular weight of 17.8 kDa. The protein includes a C-terminal 6-histidine tag and is purified using proprietary chromatographic techniques.
The IL-17E protein solution (0.5 mg/ml) is supplied in phosphate-buffered saline (pH 7.4) containing 20% glycerol.
For short-term storage (2-4 weeks), the product can be stored at 4°C. For long-term storage, freeze the product at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for extended storage. Avoid repeated freeze-thaw cycles.
Purity is determined to be greater than 95% by SDS-PAGE analysis.
Biological activity is assessed by the protein's ability to bind to human IL-17 RB in a functional ELISA assay.
interleukin-25 isoform 1, interleukin 25, IL17E, IL-17E, IL25, IL-25, interleukin-17E, interleukin-25.
HEK293.
DGSYSHWPSC CPSKGQDTSE ELLRWSTVPV PPLEPARPNR HPESCRASED GPLNSRAISP WRYELDRDLN RLPQDLYHAR CLCPHCVSLQ TGSHMDPRGN SELLYHNQTV FYRRPCHGEK GTHKGYCLER RLYRVSLACV CVRPRVMGHH HHHH
Product Science Overview
Interleukin-17E (IL-17E), also known as Interleukin-25 (IL-25), is a member of the IL-17 cytokine family. This family comprises six members, all sharing a conserved cysteine-knot structure but differing at the N-terminus . IL-17E is a proinflammatory cytokine that plays a significant role in immune responses and inflammation .
IL-17E is secreted by type 2 helper T cells (Th2) and mast cells . It binds to the IL-17RB receptor, stimulating the secretion of proinflammatory cytokines such as interleukin-8 (IL-8) and activating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) . The recombinant form of IL-17E, expressed in Human Embryonic Kidney (HEK) 293 cells, is used for various research and therapeutic purposes .
IL-17E is involved in promoting inflammatory responses. It acts by recruiting immune cells like monocytes and neutrophils to the site of inflammation . This cytokine is known to work in concert with other proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) . The activation of IL-17 signaling pathways is often observed in the pathogenesis of various autoimmune disorders, including psoriasis .
Research has shown that IL-17E has potential antitumor efficacy . Its ability to induce strong inflammatory responses makes it a candidate for cancer immunotherapy. Additionally, IL-17E’s role in autoimmune diseases suggests that targeting this cytokine could be beneficial in treating conditions like rheumatoid arthritis and multiple sclerosis .
